Biological and dosimetric evaluation of [11C]S-adenosyl methionine as a potential agent for prostate cancer diagnosis

 

Guardado en:
Detalles Bibliográficos
Autores: Zoppolo Lencina, Florencia, Mora Ramírez, Erick, Reyes Ábalos, Ana Laura, Vasilskis Castro, Elena Beatriz, Paolino Bordo, Andrea, Porcal Quinta, Williams Arturo, Oliver, Patricia, Savio Quevedo, Eduardo, Bardiès, Manuel, Engler, Henry
Formato: artículo original
Fecha de Publicación:2018
Descripción:Introduction: [11C]Choline ([11C]COL) has been widely used for prostate cancer diagnosis; however, this radiopharmaceutical is not recommended for patients with a low absolute PSA value (< 1 ng/mL) due to its limited sensitivity and specificity. The enzyme glycine N-methyltransferase is overexpressed during prostate cancer progression. It catalyses the methylation of glycine using S-adenosyl methionine (SAM or AdoMet) as a substrate. The authors have previously reported the automated radiosynthesis of [11C]SAM as a potential agent in the diagnosis of aggressive prostate cancer. In this study, a biological and dosimetric evaluation of [11C]SAM was performed. Results: The evaluation of [11C]SAM in a control group of healthy mouse model showed a relatively high tracer uptake in the kidneys and a rapid blood clearance. Most activity was eliminated in the urine. In a PC3 prostate cancer xenograft tumour model, [11C]SAM tumour uptake was significantly higher in relation to [11C]COL.The human dosimetry of [11C]SAM was estimated by extrapolating the preclinical results. The mean effective dose was 8.17 x 10-3 mSv/MBq and 2.49 x 10-3 mSv/MBq without and with bladder voiding, respectively. The results for kidneys in humans were comparable to those previously described for [11C]COL. Conclusions: The PET/CT studies showed a statistically higher in vivo tumour uptake of [11C]SAM compared to [11C]COL for the cancer xenograft model. The absorbed dose estimations of major organs and the effective dose were determined. The results suggested that [11C]SAM may be a potential PET tracer for prostate cancer diagnosis.
País:Kérwá
Institución:Universidad de Costa Rica
Repositorio:Kérwá
Lenguaje:Inglés
OAI Identifier:oai:kerwa.ucr.ac.cr:10669/88329
Acceso en línea:https://hdl.handle.net/10669/88329
Palabra clave:CANCER
prostate cancer
Glycine N-methyltransferase
PET radiotracer
small-animal PET/CT
dosimetry